More than just adipose. The impact of GLP1Ra on lean tissue.

Glucagon-like peptide 1 receptor agonists (GLP1Ra) are widely used for the management of obesity and cardiometabolic disease. While causing robust weight loss, GLP1Ra also result in reductions in lean tissue, including skeletal muscle and bone. The purpose of the current review is to discuss key findings demonstrating the effects of GLP1Ra treatment on skeletal muscle and bone, approaches that have been implemented to mitigate these changes, and to highlight important areas of future research.